chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Chills persisted for 03 weeks (occurs during the evening); fever (temperature was a little over a degree over normal); This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (Chills persisted for 03 weeks (occurs during the evening)) and PYREXIA (fever (temperature was a little over a degree over normal)) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Mar-2021, the patient experienced PYREXIA (fever (temperature was a little over a degree over normal)). On 14-Mar-2021, the patient experienced CHILLS (Chills persisted for 03 weeks (occurs during the evening)). On 15-Mar-2021, PYREXIA (fever (temperature was a little over a degree over normal)) had resolved. At the time of the report, CHILLS (Chills persisted for 03 weeks (occurs during the evening)) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant product use was reported Treatment information not provided
A non-serious report of inappropriate dose of vaccine administered was received from a nurse in the concerning a patient of an unknown age.  This case is submitted in accordance with MedImmune's post-marketing commitment on accelerated reporting for the newly indicated population of 2 years to 59 months of age for FLUMIST.  No relevant medical or drug history information was reported.  The infant was given FLUMIST on an unknown date.  The patient received one full dose of FLUMIST in each nostril.  No adverse events were reported from this error.  The reporter indicated that there would be no additional information available.  Rechallenge is not applicable.  Causality assessment is not applicable.  The reporting source of this case is spontaneous, thus the sponsor's comment is not applicable.  12-Dec-2007: Follow up information obtained and incorporated in above narrative: Availability of information.08-Jan-2008: Follow up information obtained and incorporated in above narrative: Clinical outcome.
101.5 F Fever (first and second night prior to injection) Chills (only the first night) Headache (third day) Moderate Fatigue (third day)
This was my 2nd dose. I had a sore arm, pounding headache and was very tired for 2 days.
She states on Saturday, 27th that she woke up having trouble breathing. She used VaporRub on her nose and throat and turned on her vaporizer. After about an hour, she started to feel better. But during that time, she felt like her throat was "closing" up. Her nose did not feel congested.
Triggered Minere's Disease flare up the following day, after each shot (dizziness, nausea, headache), treated successfully with typical doses of Valium.
Lymphadenopathy in the LEFT axilla.  Mild soreness at the injection site.  No redness or warmth
Pt recvd vax 12JUL; MD visit 24JUL on advice from HNA, 18JUL cold sinus infect-rx Ceclor; 22JUL rash; 24JUL drug rxn rash itching; 24JUL called MD joint pain;
Not feeling well, malaise, fatigue, intermittent upper stomach pain (sharp) beginning day after vaccine administration lasting 8 days resulting in death on 4/10/21
quadracel is not approved for patient's under the age of 4y/o with no reported adverse events; Initial information received on 15-Apr-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 18 months old and unknown gender patient who experienced quadracel is not approved for patient's under the age of 4y/o with no reported adverse events while receiving vaccine diphtheria-15/tetanus/5 hybrid ac pertussis/ipv (mrc5) vaccine [Quadracel].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included diphtheria vaccine toxoid, pertussis vaccine acellular, tetanus vaccine toxoid (dtap) for immunisation; and polio vaccine (Polio vaccine) for Immunisation.  On an unknown date, the patient received a  dose of suspect diphtheria-15/tetanus/5 hybrid ac pertussis/ipv (mrc5) vaccine  (unknown strength, dosage, formulation, batch lot number and expiry date) via unknown route in unknown administration site for immunization.  On an unknown date the patient developed a non-serious event of quadracel is not approved for patient's under the age of 4y/o with no reported adverse events (off label use) (latency :same day) following the administration ofdiphtheria-15/tetanus/5 hybrid ac pertussis/ipv (mrc5) vaccine.  Action taken: not applicable.  At time of reporting, the outcome was Unknown for the event .
I experienced bad flu symptoms. I had a fever of 103 degrees and a rash on my neck and chest area.
I wake up every 2- 3 hours and then sometimes I can't get back to sleep. Went to the doctor in August for that. He ordered a sleep study. I haven't gotten the results back yet - will see the doctor on Wednesday of this week. Note: I had COVID in March of 2020. I went to the hospital - they did a testing for COVID because they decided not to send it in. My lungs looked clear - so it was never confirmed. The second time I got it was in July 2020 - and I got tested. It resulted in positive test with that one confirmed. I had noticed sleep issues since I've had all of this. I have a really foggy brain. I don't know if it's related to sleep or vaccines - because my foggy brain keeps getting worse. I know I haven't been sleeping well. No treatment yet.
Fever; body pain; bone pain; dizziness; headache; sound in chest when breathing; hands numbness; difficulty walking; This is a spontaneous report from a contactable consumer (Patient). A 39-years-old Non pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot Number: EW0169, Expiry date was not reported), via an unspecified route of administration on 17Apr2021 17:00 (at the age of 39-years-old) in Arm right as dose 1, single for COVID-19 immunization. The patient Medical history included thyroid disorder from an unknown date and unknown if ongoing , Lactose from an unknown date and unknown if ongoing. Concomitant medications included losartan (LOSARTAN); levothyroxine (LEVOTHYROXINE); ascorbic acid, betacarotene, biotin, calcium phosphate dibasic, calcium stearate, chromic chloride hexahydrate, copper sulfate, ferrous fumarate, folic acid, magnesium oxide, manganese sulfate, nicotinamide, panax ginseng, pantothenic acid, potassium chloride, potassium iodide, pyridoxine hydrochloride, retinol, riboflavin, sodium molybdate, sodium selenate, vitamin b1 nos, vitamin b12 nos, vitamin d nos, vitamin e nos, zinc oxide (CENTRUM ACTIVE); pantoprazole (PANTOPRAZOLE) all taken for an unspecified indication, start and stop date were not reported. The patient did not received any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19 and Since the vaccination, the patient was not tested for COVID-19. On 09May2021 12:00, the patient experienced fever, body pain, bone pain, dizziness , headache, sound in chest when breathing , hands numbness, difficulty walking. The patient did not received treatment for the adverse events. The outcome for the events was not recovered.  No follow-up attempts are needed. No further information is expected.
My COVID-19 infection symptoms started on 12/12/2022 in the morning at 8:00Am. I had a scratchy throat and cough. On 12/14/2022 I did a COVID-19 home test which was positive. On the same day I went to a health facility where I got retested for COVID-19 infection, it was positive again. On 12/15/2022 I did a telehealth with my doctor he prescribed me with PAXLOVID for 5 days, and a cough syrup.
After patient received vaccines, mother and patient went to the check-out area and when mother was putting patient's socks back on she noticed blisters on the patient's toes. Patient had blisters on the bottom of both great toes and underneath all other toes.  Patient did not have any signs of difficulty breathing, no wheezing, no swelling of mouth/throat and no blisters were noted anywhere else on the patient's body. Patient was scheduled to see a local pediatrician this afternoon to be evaluated.  Mother was instructed to take patient to emergency room if she noticed patient having difficulty breathing or if blisters started to occur more.  Mother verbalized understanding of instructions.
headache; sore arm; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 37 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 16Mar2021 (Lot number: EL3247) at the age of 37 years as dose 2 single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (dose 1, Lot Number: EL3247 ), administration date: 23Feb2021, for covid-19 immunization. The following information was reported: HEADACHE (non-serious) with onset 16Mar2021, outcome "recovered", described as "headache"; PAIN IN EXTREMITY (non-serious) with onset 16Mar2021, outcome "recovered", described as "sore arm". Therapeutic measures were not taken as a result of headache, pain in extremity. No follow-up attempts are possible. No further information is expected.
Fatigue started ~ 12 hours after vaccine injection.  Muscle aches; joint pain; increased injection site pain, redness, and swelling; headache; and jaw pain started ~ 15 hours after vaccine injection.  Tylenol, Aleve, and Ibuprofen used.  Rest.
Fever. Large, painful, itchy skin hives all over scalp, forehead, cheeks, chin, neck, shoulders, abdomen and legs. Dizzy. Headaches. Earaches, ringing in the ear. Blurry vison. Difficulty driving. Started 01/17/2022 and still going on today 02/17/2022.
Sore arm; Received first dose from a vial that's been punctured for more than 30hours.; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received first dose from a vial that's been punctured for more than 30hours.) and MYALGIA (Sore arm) in a 38-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 021C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 13-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-May-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received first dose from a vial that's been punctured for more than 30hours.). On an unknown date, the patient experienced MYALGIA (Sore arm). On 13-May-2021, EXPIRED PRODUCT ADMINISTERED (Received first dose from a vial that's been punctured for more than 30hours.) had resolved. At the time of the report, MYALGIA (Sore arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No treatment information was reported    This case was linked to US-MODERNATX, INC.-MOD-2021-132835 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-132835:First patient case
LOSS OF BODILY FUNCTIONS; VOMITING; CHILLS; FEVER; DIARRHEA; TIREDNESS; LIGHT HEADINESS / DIZZINESS; This spontaneous report received from a consumer concerned a 59 year old female. The patient's weight was 80.73 kilograms, and height was 162.56 centimeters. The patient's concurrent conditions included codeine allergy, non alcohol, non smoker, breast cancer, higher blood pressure, and thyroid, and other pre-existing medical conditions included no drug abuse. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805018, expiry: UNKNOWN) dose was not reported, administered on 18-MAR-2021 13:00 for prophylactic vaccination. Concomitant medications included amlodipine for high blood pressure, hydrochlorothiazide non-company for high blood pressure, losartan for high blood pressure, and levothyroxine sodium for thyroid. On 19-MAR-2021, the subject experienced vomiting. On 19-MAR-2021, the subject experienced chills. On 19-MAR-2021, the subject experienced fever. On 19-MAR-2021, the subject experienced diarrhea. On 19-MAR-2021, the subject experienced tiredness. On 19-MAR-2021, the subject experienced light headiness / dizziness. On an unspecified date, the subject experienced loss of bodily functions. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from vomiting, chills, fever, diarrhea, tiredness, and light headiness / dizziness on 21-MAR-2021, and was recovering from loss of bodily functions. This report was non-serious.  Additional information was received from ( patient) on 09-apr-2021. The following information was updated and incorporated into the case narrative; Event details( light headiness subsummed into dizziness, diarrhea, tiredness) Products ( amlodipine, hydrochlorothiazide, losartan, euthyrox), Disease ( high blood pressure, thyroid ,breast cancer) Labelling(diarrhea, tiredness,) Causality(diarrhea, tiredness),Outcome ( diarrhea, tiredness),Anatomical site( right arm), Time of vaccination (13.00), Chemotherapy was added in disease tab as it was given in 2006.; Sender's Comments: V0: Medical assessment comment not required as per standard procedure since case was assessed as non serious.
This spontaneous report was received from a pharmacist and refers to a patient of unknown age and gender. No information about the patient's medical history, concurrent conditions, drug reactions or allergies and concomitant therapies was provided. On 06-JAN-2017 at 13:43 the patient was vaccinated with improperly stored VARIVAX injection (lot # M035142) ( expiration date, dose and route of administration were not reported). The vaccine underwent previous temperature excursions. The number of previous excursions, time frames and values of incorrect temperature were unknown. No adverse effects were reported. Digital data logger was used. Product quality complaint was not involved. This is one of several reports received from the same reporter. Additional information has been requested.; Sender's Comments: US-009507513-1701USA008441: US-009507513-1704USA000389: US-009507513-1704USA000390: US-009507513-1704USA000391: US-009507513-1704USA000392: US-009507513-1704USA000393: US-009507513-1704USA000394: US-009507513-1704USA000396: US-009507513-1704USA000397: US-009507513-1704USA000398: US-009507513-1704USA000399: US-009507513-1704USA000400: US-009507513-1704USA000401: US-009507513-1704USA000402: US-009507513-1704USA000403: US-009507513-1704USA000404: US-009507513-1704USA000405: US-009507513-1704USA000406: US-009507513-1704USA000407: US-009507513-1704USA000408: US-009507513-1704USA000409: US-009507513-1704USA000410: US-009507513-1704USA000411: US-009507513-1704USA000412: US-009507513-1704USA000413: US-009507513-1704USA000414: US-009507513-1704USA000415: US-009507513-1704USA000416: US-009507513-1704USA000417: US-009507513-1704USA000418: US-009507513-1704USA000419: US-009507513-1704USA000420: US-009507513-1704USA000421: US-009507513-1704USA000422: US-009507513-1704USA000423: US-009507513-1704USA000424: US-009507513-1704USA000425: US-009507513-1704USA000426: US-009507513-1704USA000427: US-009507513-1704USA000428: US-009507513-1704USA000429: US-009507513-1704USA000430: US-009507513-1704USA000431: US-009507513-1704USA000432: US-009507513-1704USA000433: US-009507513-1704USA000434: US-009507513-1704USA000435: US-009507513-1704USA000436: US-009507513-1704USA000437: US-009507513-1704USA000438: US-009507513-1704USA000439: US-009507513-1704USA000440: US-009507513-1704USA000441: US-009507513-1704USA000442: US-009507513-1704USA000443: US-009507513-1704USA000444: US-009507513-1704USA000445: US-009507513-1704USA000446: US-009507513-1704USA000447: US-009507513-1704USA000448: US-009507513-1704USA000449: US-009507513-1704USA000450: US-009507513-1704USA000451: US-009507513-1704USA000452: US-009507513-1704USA000453: US-009507513-1704USA000454: US-009507513-1704USA000455: US-009507513-1704USA000456: US-009507513-1704USA000457:
TROUBLE BREATHING; A RASH ALONG THE THIGHS LIKE SMALL SPOTS ON THE INNER THIGHS THE SIZE OF HALF DOLLAR WHEN IT FIRST STARTED IT SPREAD DOWN TO CALF TO STOMACH AND TORSO AND UP TO CHEST; NAUSEA; HEADACHE; FEVER SPIKED TO 102 F; BODY ACHES; HEART RATE WENT UP; This spontaneous report received from a parent concerned an 18 year old female. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included the patient has no known drug allergies and patient had no underlying health conditions. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 206A21A and expiry: 23-JUN-2021) dose was not reported, administered on 02-MAY-2021 15:00 for prophylactic vaccination. No concomitant medications were reported.  On 02-MAY-2021, the subject experienced body aches. On 02-MAY-2021, the subject experienced heart rate went up. On 02-MAY-2021, the subject experienced a rash along the thighs like small spots on the inner thighs the size of half dollar when it first started it spread down to calf to stomach and torso and up to chest. On 02-MAY-2021, the subject experienced nausea. On 02-MAY-2021, the subject experienced headache. On 02-MAY-2021, the subject experienced fever spiked to 102 f. Laboratory data included: Heart rate (NR: not provided) from 115, 120 to125. On 03-MAY-2021, the subject experienced trouble breathing. Laboratory data included: Body temperature (NR: not provided) 102 F, Below 100 F, and Laboratory test (NR: not provided) unknown. On 04-MAY-2021, treatment medications included: salbutamol. Laboratory data (dates unspecified) included: Chest X-ray (NR: not provided) Unknown, and Laboratory test (NR: not provided) Unknown. Additional treatment medications (dates unspecified) included: paracetamol, and ibuprofen. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from a rash along the thighs like small spots on the inner thighs the size of half dollar when it first started it spread down to calf to stomach and torso and up to chest, and fever spiked to 102 f on JUL-2021, and the outcome of nausea, heart rate went up, trouble breathing, headache and body aches was not reported. This report was non-serious. This case, from the same reporter is linked to 20210755447.
His immediate side effects from the 1st dose of the COVID Moderna vaccine in  8/29/22, he complained of soreness at the injection site, but he was fine.  Shortly after, he got a cold with fever and really rough, phlegmy cough.  He got better and then we gave him the 2nd dose on 10/11/22.  Side effects were the same as the first.  Then on 11/4/22, he developed a fever and bad cough.  Was very low energy and would need to be picked up because was too weak to walk. We sent him to the pediatrician, who ruled out RSV and COVID.  But later that night, his fever was really high (~104)and cough sounded like high pitched barks and his voice was also high pitched.  When he gets severe coughs like this, it's very hard for him to breathe and his heart rate sky rockets.  We took him to the ER.  They Dx him with croup and treated him with steroids.  Discharged without medication.  On 11/7/22, we brought him to the pediatrician again because he started throwing up and he couldn't hold any liquids or food down.  His cough was so severe that he would cough until he threw up.  She told us to bring him to the ER again because what might have started as viral may be exacerbated by bacteria infection.  She wanted us to get an xray for pneumonia.  We went to ER and he was put on oxygen, IV for fluids (which he needed because he hadn't been able to drink), and steroids again.  Chest xray was not definitive for pneumonia, but doctors suspected that it could be the beginning of pneumonia, so he was discharged with amoxicillin.  Since administering amox, he has been much better.  Energy level returned, but cough lingers.  Appetite is back.  Today, 11/11/22, cough is sporadic.  He still sometimes goes into coughing fits, but not to the point of incapacitation like before.
Fever 24 hours after vaccines. Afebrile seizure, generalized, brief 1/2 hour after fever discovered.
Patient received CoVID vaccine #1 in drive thru lane.  Approx 10minutes after vaccine patient driver reported something was wrong with patient.  When patient was assessed, it appeared she was having a seizure.  Medical alert called.  Driver stated patient had history of seizures, but was not a good historian of medical information.  EMS transported patient to ED.
Vaccinations were performed through our health team on site. Both Moderna and Janssen were being offered on site. Patient consented to Janssen as his first COVID vaccine on 03/31/2021. It is possible he received Moderna vaccine instead because both types of vaccine were being prepared/administered at nearby stations. Patient notified of possible error.  Mild arm soreness for 1 day. No adverse events as of 04/08/2021 after following up with patient via telephone.  informed and advised for patient to receive 2nd Moderna vaccine 28-42 days after initial vaccine due to our uncertainty as to which vaccine he received on 03/31/2021.
A very slight headache starting approximately 4 hours post vaccination.; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: CN6206) via an unspecified route of administration in the right arm on 16Mar2021 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies to medications, food or other products. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 16Mar2021 at 16:00, approximately 4 hours post vaccination, the patient experienced a very slight headache. Additionally on 20Mar2021, four days after vaccination, the patient donated blood, which was a regular occurrence for him. On an unknown date in 2021, he received word back from his donation that he had a reactive result on the anti-HCV screening. Extra testing indicated that this result was a false positive and that he did not show any reactivity to the anti-HCV test. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event slight headache was resolved on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.